PREX2 pcdna3.1 V5/his Citations (3)

Originally described in: Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.
Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, Hibshoosh H, Parsons R Science. 2009 Sep 4;325(5945):1261-5. PubMed Journal

---

Articles Citing PREX2 pcdna3.1 V5/his

Articles
CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, Wang M, Zhou L, Li T, Li X, Bode AM, Dong Z. Carcinogenesis. 2019 Jun 25. pii: 5523300. doi: 10.1093/carcin/bgz113. PubMed
Tumorigenesis driven by the BRAF(V600E) oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion. Gadal S, Boyer JA, Roy SF, Outmezguine NA, Sharma M, Li H, Fan N, Chan E, Romin Y, Barlas A, Chang Q, Pancholi P, Timaul NM, Overholtzer M, Yaeger R, Manova-Todorova K, de Stanchina E, Bosenberg M, Rosen N. bioRxiv [Preprint]. 2024 Apr 20:2023.11.21.568071. doi: 10.1101/2023.11.21.568071. PubMed
AHCYL1 mediates the tumor-promoting effect of PREX2 in non-small cell lung carcinoma. Lei M, Yeung YT, Nie W, Yang R, Li J, Chen H, Zhao R, Liu K, Dong Z. Theranostics. 2025 Apr 21;15(12):5772-5789. doi: 10.7150/thno.108654. eCollection 2025. PubMed

If you have published an article using this material, please email us at to have your article added to this page.